ACRE Charter Meeting's Unofficial Press Packet

In all the hoopla and excitement of forming a new organization such as ACRE, certain minor details are easy to overlook. One of these details is a listing of financial disclosures, which is conspicuously missing from the ACRE website. In the spirit of helpfulness and tying up loose ends, here is a partial list of industry disclosures that might otherwise get lost in the shuffle.

Thomas P. Stossel, MD American Cancer Society Professor of Medicine Harvard Medical School Director, Translational Medicine Division Senior Physician, Hematology Division Brigham & Women's Hospital Senior Fellow, Manhattan Institute for Policy Research

Disclosure: Thomas P. Stossel, MD, has disclosed that he is on the Board of Directors for ZymeQuest, Inc. and Critical Biologics Corporation. Dr. Stossel has also disclosed that he owns stock options in ZymeQuest, Inc. and stock options and stock in Critical Biologics Corporation. Dr. Stossel has also disclosed that he has received a consulting fee from Critical Biologics Corporation and that he is a paid lecturer at corporations.

Source: Dr. Stossel's response to the AMA's ethics council's recommendations to limit industry funding of medical education.

Henry R. Black, MD, MA Hypertension Division, New York University Medical Center, President, American Society of Hypertension

Disclosure: Henry R. Black, MD, has disclosed that he has served as an advisor or consultant for Pfizer, Bristol-Myers Squibb, IntraCure, sanofi-aventis, Merck Sharp & Dohme, Forest Laboratories, Daiichi Sankyo, Boehringer Ingelheim, and CV Therapeutics.
Source: http://www.medscape.com/viewarticle/572474

Jeffrey S. Flier, MD Dean, Harvard Medical School, Carolyn Shields Walker Professor of Medicine

Disclosure: Previously received a $500,000 research grant from Bristol-Myers Squibb. He also consulted for three Cambridge biotechnology companies, but says that those relationships have ended and that he has accepted no new industry affiliations.

Source: This New York Times article on conflicts of interest at Harvard Medical School.

Rafael F. Fonseca, MD, PhD Mayo Clinic Arizona, Consultant, Professor of Medicine Deputy Director Mayo Clinic Cancer Center

Disclosure: Consultant for Amgen Inc., Genzyme Corporation, Medtronic. Speaker's Bureau for Celgene Corporation, Millennium Pharmaceuticals, Inc.

Source: The Center for Biomedical Continuing Education, a MECC specializing in industry-funded CME programs.

Jeffrey R. Garber, MD, FACP, FACE Beth Israel Deaconess Medical Center; Harvard Vanguard Medical Associates, President, American Association of Clinical Endocrinologists

Disclosure: Consultant to KingPharmaceuticals and Abbott Laboratories.

Source: Abbott-funded CME supplement to the Journal of Family Practice.

J Michael Gonzalez-Campoy, MD, PhD, FACE Medical Director and CEO, MNCOME, Member, AACE Board of Directors

Disclosure: Research funding from Leptos and Sanofi-Aventis

Source: Website of the Minnesota Center for Obesity, Metabolism, and Endocrinology

Simon M. Helfgott, MD Associate Professor of Medicine, Harvard Medical School, Director of Education, and Fellowship Training, Division of Rheumatology, Brigham and Women's Hospital

Disclosure: Consultant for Teva Pharmaceuticals; advisor and speaker's bureau for both Centocor and Genentech.

Source: Website of PRIME, a MECC specializing in industry-funded medical education.

Avi B. Markowitz, MD Bill and Louise Bauer Distinguished Chair in Cancer Research, Professor and Chief, Division of Hematology/Oncology, Associate Clinical Director and Department Head of the Office of Oncology Clinical Trials, UTMB Comprehensive Cancer Center, University of Texas Medical Branch

Disclosure: Research funding from Alexion, Amgen, Anthera, Bristol-Myers Squibb, Eli Lilly, Johnson and Johnson, Genentech, MGI Pharma, Ortho Biotech.

Source: CV of Avi Markowitz.

Paul G. Richardson, MD Associate Professor of Medicine, Harvard Medical School, Clinical Director, Jerome Lipper Center for Multiple Myeloma, Dana-Farber Cancer Institute

Disclosure: Honoraria, Celgene Corporation, Millenium Pharmaceuticals

Source: Millenium Pharmaceuticals-supported CME program